Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Esperion Therapeutics, Inc. (ESPR) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Esperion is a commercial-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the symbol ESPR, and its filings offer detailed insight into its cardiometabolic and rare/orphan disease business, including oral non-statin LDL-C therapies such as NEXLETOL and NEXLIZET.
Key filing types for Esperion include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, financial statements, and discussion of operations. Current reports on Form 8-K and 8-K/A, several of which are referenced in the provided data, disclose material events such as financial results, underwritten public offerings of common stock, executive appointments, board changes, and other significant corporate developments.
Investors can also review notifications of late filing on Form 12b-25, which explain delays in periodic reports and provide management’s narrative regarding the status of financial closing procedures. For Esperion, these documents have included explanations related to quarterly financial close and corrections to previously furnished earnings releases.
On Stock Titan, Esperion’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the content of lengthy documents, highlight key sections, and surface items such as revenue drivers, commercialization plans for NEXLETOL and NEXLIZET, capital-raising transactions, and changes in executive leadership. Users can also identify trading symbol information, exchange listing details, and other disclosures related to Esperion’s common stock directly from these filings.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) has appointed Craig Thompson, MBA, a veteran biotechnology executive, to its Board of Directors effective July 1, 2025. Thompson will serve as an independent Class II director with a term running through the 2027 annual meeting. He will immediately join the Compliance, Nominating & Corporate Governance, and Commercial Committees.
Thompson brings more than two decades of commercial and C-suite experience to Esperion. He is currently CEO of Cerevance, LLC and holds board seats at NervGen Pharma. His prior leadership roles include CEO positions at Neurana, Anthera and senior commercial posts at Tetraphase, Trius, Pfizer and Merck, where he helped launch high-profile cardiovascular products such as Zocor and oversaw the global commercial development of torcetrapib/atorvastatin.
Under Esperion’s non-employee director compensation plan, Thompson will receive standard cash retainers and equity awards. The company has executed a customary indemnification agreement with him. No related-party transactions were disclosed.
A press release announcing the appointment was furnished as Exhibit 99.1 under Item 7.01; the disclosure is deemed “furnished” and not “filed” under the Exchange Act.
The Form 4 filed on 18 June 2025 shows that Esperion Therapeutics (ESPR) General Counsel Benjamin Looker sold 6,422 common shares on 17 June 2025 at an average price of $1.152 per share. A footnote clarifies the disposition was made solely to cover withholding taxes on recently vested RSUs, and the transaction was coded “S.” After the sale, Looker continues to hold 401,241 ESPR shares directly, meaning the divestiture equals roughly 1.6 % of his post-transaction stake. No derivative securities were exercised or disposed of.
Because the sale is small relative to the insider’s total ownership and is expressly tax-related, it is typically regarded as routine and low-impact for valuation or governance considerations. Nevertheless, investors tracking insider sentiment may note that the execution price signals the insider’s willingness to transact around the $1.15 level.
Form 4 highlights: Esperion Therapeutics (ESPR) President & CEO Sheldon L. Koenig reported the sale of 30,474 common shares on 06/17/2025 at an average price of $1.109 per share, transaction code “S”. Following the disposition, Koenig directly owns 1,541,488 ESPR shares.
The filing notes that the shares were sold solely to cover tax-withholding obligations incurred from the vesting of restricted stock units; the sale was not part of an open-market liquidation for personal gain. No derivative securities were acquired or disposed of, and no Rule 10b5-1 trading plan was indicated.
Because the sale represents roughly 2 % of Koenig’s direct holdings and leaves his ownership position largely intact, the transaction appears routine and is unlikely to materially affect investor perceptions of insider alignment or corporate governance.
Esperion Therapeutics (ESPR) – Form 4 insider filing: Chief Financial Officer Benjamin Halladay reported the sale of 7,229 common shares on 06/17/2025 at $1.152 per share, generating roughly $8,300 in proceeds. The company states the disposition was made solely to cover withholding taxes on recently-vested RSUs. Following the transaction, Halladay still directly holds 474,473 ESPR shares. No derivative transactions or additional dispositions were disclosed, and the filing indicates the sale was effected under a routine tax-settlement, not a 10b5-1 trading plan.